Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Calando Pharmaceuticals to Present at 19th Annual Oppenheimer Healthcare Conference on November 4, 2008

Abstract:
Calando Pharmaceuticals, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today that its CEO, Dr. James Hamilton, will present at the 19th Annual Oppenheimer Healthcare Conference on Tuesday, November 4, 2008 at 11:00am ET. The conference is being held at the Waldorf Astoria Hotel in New York City. Dr. Hamilton's presentation will discuss Calando's proprietary delivery systems for siRNA and small molecule drugs and Calando's clinical program for its two lead compounds, CALAA-01 and IT-101.

Calando Pharmaceuticals to Present at 19th Annual Oppenheimer Healthcare Conference on November 4, 2008

PASADENA, CA | Posted on November 3rd, 2008

CALAA-01, currently undergoing a Phase I clinical trial, is believed to be the first siRNA therapeutic to enter the oncology clinic. To our knowledge, it is also the first systemically delivered siRNA therapeutic formulated with a targeted delivery system. Calando's RONDEL™ delivery system was developed to address the long-standing obstacle of effective delivery and targeting for this potentially revolutionary new class of pharmaceuticals. CALAA-01 is a targeted nanoparticle comprised of a patented, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase, a clinically-validated cancer target and the RONDEL system.

IT-101, Calando's lead candidate delivering a small molecule drug, began clinical trials in 2006. IT-101 demonstrated safety and favorable pharmacokinetic properties in Phase I clinical trials and is currently undergoing a Phase II clinical trial. IT-101 is a conjugate of Cyclosert™, Calando's proprietary delivery system for small molecule drugs, and camptothecin. Both RONDEL™ and Cyclosert™ utilize modified cyclodextrin molecules to create an entirely new class of drug delivery materials, which Calando believes have the ability to solve many of the deficiencies observed in therapeutic product candidates.

Forward-Looking Statements

This news release, and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on Calando's management current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, among others: the risk that CALAA-01 or IT-101 may appear promising in early research and clinical trials but may not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risks that the regulatory approvals may not be obtained, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; and risks associated with our ability to protect our intellectual property and raise the necessary financing to fund our operations and research activities. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

####

For more information, please click here

Contacts:
Calando Pharmaceuticals, Inc.
James C. Hamilton M.D.
626-683-7200

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Two-dimensional melting of hard spheres experimentally unravelled after 60 years: First definitive experimental evidence of two-dimensional melting of hard spheres April 21st, 2017

National Conference on Nanomaterials, (NCN-2017) April 21st, 2017

NanoMONITOR shares its latest developments concerning the NanoMONITOR Software and the Monitoring stations April 21st, 2017

Nanomechanics, Inc. Unveils New Product at ICMCTF Show April 25th: Nanoindentation experts will launch the new Gemini that measures the interaction of two objects that are sliding across each other – not merely making contact April 21st, 2017

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Caught on camera -- chemical reactions 'filmed' at the single-molecule level March 22nd, 2017

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

Nanomedicine

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Nano-SPEARs gently measure electrical signals in small animals: Rice University's tiny needles simplify data gathering to probe diseases, test drugs April 17th, 2017

Nanotubes that build themselves April 14th, 2017

Emergency Use Authorization for Gene-RADAR® Zika Virus Test: FDA Authorization for the Gene-RADAR® Zika Virus Test on the XPRIZE-Winning Gene-RADAR® Platform April 14th, 2017

Announcements

Two-dimensional melting of hard spheres experimentally unravelled after 60 years: First definitive experimental evidence of two-dimensional melting of hard spheres April 21st, 2017

National Conference on Nanomaterials, (NCN-2017) April 21st, 2017

NanoMONITOR shares its latest developments concerning the NanoMONITOR Software and the Monitoring stations April 21st, 2017

Nanomechanics, Inc. Unveils New Product at ICMCTF Show April 25th: Nanoindentation experts will launch the new Gemini that measures the interaction of two objects that are sliding across each other – not merely making contact April 21st, 2017

Events/Classes

National Conference on Nanomaterials, (NCN-2017) April 21st, 2017

Nanomechanics, Inc. Unveils New Product at ICMCTF Show April 25th: Nanoindentation experts will launch the new Gemini that measures the interaction of two objects that are sliding across each other – not merely making contact April 21st, 2017

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project